Transcatheter aortic valve implantation without balloon predilation: A single-center pilot experience

Aim To assess the results of transcatheter aortic valve implantation (TAVI) using the Medtronic CoreValve prosthesis (Medtronic, Minneapolis, MN), without balloon predilation, in high‐risk patients with degenerated severe aortic stenosis. Methods and Results Fifty‐one consecutive patients who underw...

Full description

Saved in:
Bibliographic Details
Published inCatheterization and cardiovascular interventions Vol. 82; no. 2; pp. 292 - 297
Main Authors Mendiz, Oscar A., Fraguas, Hugo, Lev, Gustavo A., Valdivieso, Leon R., Favaloro, Roberto R.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.08.2013
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Aim To assess the results of transcatheter aortic valve implantation (TAVI) using the Medtronic CoreValve prosthesis (Medtronic, Minneapolis, MN), without balloon predilation, in high‐risk patients with degenerated severe aortic stenosis. Methods and Results Fifty‐one consecutive patients who underwent direct TAVI, 98% through a transfemoral approach. Patients were 79 ± 8 years of age, 74% in New York Heart Association classes III or IV and at high risk for surgical valve replacement (mean logistic EuroScore 20 ± 15). Mean aortic valve area was 0.7 ± 0.2 cm2. Procedural success rate was 94.2%. In‐hospital, there were 2 deaths, 1 minor stroke with minimal sequelae, and 14 (28%) pacemaker implantation. At 30 days, there was one additional stroke and no new deaths. The mean postprocedural transprosthetic gradient was 15 ± 5 mm Hg; periprosthetic severe regurgitation was absent and moderate in one case. After a median follow‐up of 7 months, there were five additional deaths (two cardiac), while 84% of survivors were in New York Heart Association classes I or II. Conclusions These results suggest that direct CoreValve implantation in patients with severe aortic stenosis is feasible and may lead to hemodynamic and clinical improvement in patients who are poor candidates for aortic valve surgery, pending confirmation in larger series with longer follow‐up. © 2013 Wiley Periodicals, Inc.
Bibliography:istex:1CB95E2684B2DFBCCA0A7E058191F467B15DEF32
ArticleID:CCD24805
ark:/67375/WNG-3CHMSS5X-7
Conflict of interest: Oscar Mendiz MD, FSCAI: Proctor Medtronic for CoreValve, speacker honorarium.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.24805